Results 11 to 20 of about 28,272 (264)

Reduced Serum Soluble L-Selectin Levels but Not PCSK9 May Be Associated With Generalized Anxiety Disorder: A Case-Control Study. [PDF]

J Clin Lab Anal
The study included 88 generalized anxiety disorder (GAD) patients and 88 age and sex‐matched healthy controls (HCs). A psychiatrist confirmed the GAD diagnosis, assessed symptom severity using the GAD‐7 scale, and evaluated controls based on the DSM‐5 criteria.
Munny FA, Pranto AH, Paul S, Haque MA, Sharmin R, Sultana S, Hossain MA, Islam MR.   +7 more
europepmc   +2 more sources

Proprotein Convertase Subtilisin Kexin 9 Inhibitors [PDF]

Cardiology Clinics, 2018
High levels of low-density lipoprotein cholesterol (LDL-C) are directly associated with an increased risk of cardiovascular disease. Reducing LDL-C levels reduces the incidence of cardiovascular events. Several lipid-lowering approaches are available to achieve the LDL-C levels recommended by current guidelines, statins being the first-line therapy ...
Angela Pirillo, Alberico L. Catapano
openalex   +4 more sources

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism

Hepatology, EarlyView., 2022
Hepatic APOF transcript levels correlate inversely with plasma TG and hepatic steatosis in humans. ApoF expression in mice promotes VLDL‐TG production and lipoprotein remnant clearance in mice. Abstract Background NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD,
Audrey Deprince, Nathalie Hennuyer, Sander Kooijman, Amanda C. M. Pronk, Eric Baugé, Viktor Lienard, An Verrijken, Eveline Dirinck, Luisa Vonghia, Eloïse Woitrain, Niels J. Kloosterhuis, Eléonore Marez, Pauline Jacquemain, Justina C. Wolters, Fanny Lalloyer, Delphine Eberlé, Sandrine Quemener, Emmanuelle Vallez, Anne Tailleux, Mostafa Kouach, Jean‐Francois Goossens, Violeta Raverdy, Bruno Derudas, Jan Albert Kuivenhoven, Mikaël Croyal, Bart van de Sluis, Sven Francque, François Pattou, Patrick C. N. Rensen, Bart Staels, Joel T. Haas   +30 more
wiley   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 Induces Platelet-Derived Transforming Growth Factor-<i>β</i> to Promote Myocardial Fibrosis After Myocardial Infarction. [PDF]

Hum Mutat
Aims The recovery of cardiac function after acute myocardial infarction is crucial for the prognosis of patients with myocardial infarction. Proprotein convertase subtilisin/Kexin Type 9 (PCSK9) inhibitors are widely used in patients with acute myocardial infarction due to their potent low‐density lipoprotein‐lowering effects. Recent studies have shown
Wang Q, Huang W, Xia D, Wang F, Nair S.
europepmc   +2 more sources

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors [PDF]

Canadian Medical Association Journal, 2019
PCSK9 is a protease that degrades hepatic LDL-C receptors. Evolocumab and alirocumab are fully human monoclonal antibodies administered as subcutaneous injections that inhibit PCSK9, preserving receptor availability to clear circulating LDL-C.[1][1],[2][2] In randomized, placebo-controlled ...
Derek, Leong, Peter E, Wu
openaire   +2 more sources

Antioxidant Activity and Potential Cholesterol Modulating Effect of Punica granatum L. Peel Hydroethanolic Extract. [PDF]

Chem Biodivers
Punica granatum peel extract is rich in phenolic compounds, exhibits strong antioxidant activity, and modulates the expression of PCSK9 and LDL receptors. Collectively, these findings suggest a potential cardioprotective effect of the extract. ABSTRACT Lipoprotein metabolism is regulated by several key proteins, notably proprotein convertase subtilisin/
Chaaba R, Nakbi A, Rossi I, Jrah H, Amri Z, Ferri N, Hammami S, Dall'Acqua S, Hammami M, Mehri S.   +9 more
europepmc   +2 more sources

The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9 [PDF]

Pharmacological Reviews, 2017
The secretory proprotein convertase (PC) family comprises nine members, as follows: PC1/3, PC2, furin, PC4, PC5/6, paired basic amino acid cleaving enzyme 4, PC7, subtilisin kexin isozyme 1/site 1 protease (SKI-1/S1P), and PC subtilisin/kexin type 9 (PCSK9).
Nabil G, Seidah, Marianne, Abifadel, Stefan, Prost, Catherine, Boileau, Annik, Prat   +4 more
openaire   +2 more sources

Proprotein convertase subtilisin/kexin type 9 and lipid metabolism [PDF]

Current Opinion in Lipidology, 2019
Purpose of review The purpose of this review is to highlight the recent findings of one of the most promising therapeutic targets in LDL cholesterol (LDL-C) management, proprotein convertase subtilisin/kexin type 9 (PCSK9).
Stefano, Spolitu, Wen, Dai, John A, Zadroga, Lale, Ozcan   +3 more
openaire   +2 more sources

Unpacking and understanding the impact of proprotein convertase subtilisin/kexin type 9 inhibitors on apolipoprotein B metabolism [PDF]

, 2017
No abstract ...
Packard, Chris J.
core   +1 more source

Discovery and SAR analysis of phenylbenzo[d][1,3]dioxole-based proprotein convertase subtilisin/kexin type 9 inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel therapeutic target for the development of cholesterol-lowering drugs.
Fahui Li, Lihui Zhang, Jinhong Feng, Lei Zhang   +3 more
doaj   +1 more source